Leslie Tari
Director Técnico/Científico/I+D en CIDARA THERAPEUTICS, INC. .
Fortuna: 235 666 $ al 31/05/2024
Perfil
Leslie Tari was the founder of ActiveSight, a company founded in 2003, where he held the title of Director-Structural Biology from 2003 to 2007.
He is also currently working as the Chief Scientific Officer at Cidara Therapeutics, Inc. since 2013.
In the past, Dr. Tari worked as a Member-Scientific Staff at Syrrx, Inc. from 2001 to 2003 and as Vice President-Drug discovery at Trius Therapeutics, Inc. from 2007 to 2014.
Dr. Tari obtained his undergraduate and doctorate degrees from the University of Manitoba.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
15/03/2024 | 18 571 ( 0.41% ) | 235 666 $ | 31/05/2024 |
Cargos activos de Leslie Tari
Empresas | Cargo | Inicio |
---|---|---|
CIDARA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/03/2019 |
Antiguos cargos conocidos de Leslie Tari.
Empresas | Cargo | Fin |
---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2014 |
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Fundador | 01/01/2007 |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 01/01/2003 |
Formación de Leslie Tari.
University of Manitoba | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Distribution Services |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Leslie Tari